William Blair Downgrades Sequenom, Citing Coding Issues and Increased Competition; Shares Down Sharply | GenomeWeb

NEW YORK (GenomeWeb News) — William Blair today downgraded Sequenom after the San Diego-based company firm missed Wall Street estimates on the top and bottom lines in its second quarter.

After the earnings release shares of Sequenom were down as much as 56 percent today amid heavy trading.

Analyst Brian Weinstein downgraded Sequenom to Market Perform from Outperform and lowered his revenue estimate for full-year 2013 to $166.4 million from $200.4 million. He also lowered adjusted net loss estimates to $.87 per share from an earlier estimate of $.72 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.